Gyre Therapeutics presents a paradoxical profile, combining elite gross margins consistently above 92% with a deteriorating operational model that generated a -49.3% operating margin in 2026Q2. The company's growth trajectory is highly volatile, with revenue g...
Price trend, volume and key moving averages
Trailing total returns as of 10/22/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 7, 2026 | -$0.12-111.8% vs -$0.06 | $29M+9.9% vs $26M |
Q2 2026 May 7, 2026 | -$0.05+16.7% vs -$0.06 | $23M-28.8% vs $32M |
Q2 2026 Mar 12, 2026 | -$0.02-133.4% vs $0.06 | $37M+5.0% vs $35M |
Q4 2025 Nov 7, 2025 | $0.06+20.0% vs $0.05 | $31M-7.2% vs $33M |
Gyre Therapeutics (NASDAQ: GYRE - Get Free Report) and Traws Pharma (NASDAQ: TRAW - Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, valuation, profitability, earnings, risk, institutional ownership and analyst recommendations. Analyst Recommendations This is a breakdown of
SAN DIEGO, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Gyre Therapeutics, Inc. (Gyre, Gyre Therapeutics or the Company) (Nasdaq: GYRE), an innovative, commercial-stage biopharmaceutical company with operations in the United States and China, today announced that Company management will participate in the Cantor Global Healthcare Conference and the Morgan Stanley Healthcare Conference, both being held this month in New York, NY.
Gyre Therapeutics, Inc. (GYRE) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to earnings of $0.02 per share a year ago.
Q2 2026 revenue of $29.1 million; GAAP basic EPS: $(0.12) Full year 2026 revenue guidance of $100.5 to $111.0 million affirmed NDA for F351 (hydronidone) for CHB-induced liver fibrosis accepted by China's CDE in May 2026 SAN DIEGO, Aug. 07, 2026 (GLOBE NEWSWIRE) -- Gyre Therapeutics, Inc. (Gyre, Gyre Therapeutics or the Company) (Nasdaq: GYRE), an innovative, commercial-stage biopharmaceutical company with operations in the United States and China, today announced financial results for the second quarter ended June 30, 2026, and provided a business update. Dr. Ying Luo, President and Chief Executive Officer of Gyre Therapeutics, commented, “I am very pleased with Gyre's progress over this last quarter, the highlights of which include the acquisition of Cullgen with its robust degrader pipeline and strong executive team, the NMPA acceptance of an NDA for F351 for CHB liver fibrosis, Gyre's second major product candidate after ETUARY™, and increased sales from our Gyre Pharmaceuticals division, which demonstrates our commercialization capabilities.
Benchmark GYRE against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Gyre Therapeutics, Inc. (GYRE)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $5.90 | $539.21M | 262.22 | 10.24% | 4.31% | 4.18% | — | |
| $124.83 | $14.81B | 48.76 | 37.55% | 24.86% | 180.63% | — | |
| $3.13 | $773.2M | -12.04 | 22.09% | -12.35% | -36% | — | |
| $256.86 | $7.16B | -19.05 | -100% | — | -34.15% | — | |
| $20.19 | $3.46B | 8.82 | 11.87% | 33.42% | 32.39% | — | |
| $20.91 | $1.54B | 6.34 | 18.52% | 80.56% | 30.03% | — |
Gyre Therapeutics, Inc. (GYRE) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Gyre Therapeutics, Inc. (GYRE) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 7, 2026·SEC
Jul 16, 2026·SEC
Jun 16, 2026·SEC
Get notified when GYRE posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Gyre Therapeutics, Inc. (GYRE) stock FAQ — growth, dividends, profitability & financials explained
Gyre Therapeutics, Inc. (GYRE) reported $119.4M in revenue for fiscal year 2025. This represents a 3093% increase from $3.7M in 2004.
Gyre Therapeutics, Inc. (GYRE) grew revenue by 10.2% over the past year. This is steady growth.
Gyre Therapeutics, Inc. (GYRE) reported a net loss of $17.3M for fiscal year 2025.
Gyre Therapeutics, Inc. (GYRE) has a return on equity (ROE) of 4.2%. This is below average, suggesting room for improvement.
Gyre Therapeutics, Inc. (GYRE) had negative free cash flow of $16.8M in fiscal year 2025, likely due to heavy capital investments.
